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Summary
Background Extended-spectrum β-lactamase-producing Escherichia coli isolates (ESBL-E coli) cause more than 
5000 cases of bacteraemias annually in the UK. The contribution of the food chain to these infections is debated. 
We aimed to identify the most important reservoirs of ESBL-E coli that colonise and infect humans to identify strategic 
intervention points.
Methods Sampling for ESBL-E coli was done between Aug 1, 2013, and Dec 15, 2014. We used selective media to seek 
ESBL-E coli in routinely submitted samples from human faeces, and prospectively collected samples from sewage, farm 
slurry, and retail foodstuffs in London, East Anglia, northwest England, Scotland, and Wales. We sequenced recovered 
isolates and compared these isolates with 293 bloodstream and 83 veterinary surveillance ESBL-E coli isolates from the 
same regions.
Findings 2157 (11%) of 20 243 human faeces samples contained ESBL-E coli, including 678 (17%) of 3995 in London. 
ESBL-E coli also were frequent in sewage and retail chicken (104 [65%] of 159 meat samples), but were rare in other 
meats and absent from plant-based foods (0 of 400 fruit and vegetable samples). Sequence type (ST) 131 dominated 
among ESBL-E coli from human blood (188 [64%] of 293 isolates), faeces (128 [36%] of 360), and sewage (14 [22%] 
of 65) with STs 38 and 648 also widespread; CTX-M-15 was the predominant ESBL in these lineages (319 [77%] 
of 416). By contrast, STs 602, 23, and 117—mostly with CTX-M-1 ESBL—dominated among food and veterinary 
isolates (68 [31%] of 218), with only two ST131 organisms recovered. ST10 occurred in both animals and humans, 
being frequent in surveillance bovines (11 [22%] of 51 cattle) and representing 15 (4%) of 360 human faecal isolates 
(but only three [1%] of 293 from bacteraemias); however, both human and animal ST10 isolates were diverse in 
serotype.
Interpretation Most human bacteraemias with ESBL-E coli in the UK involve internationally prevalent human-
associated STs, particularly ST131; non-human reservoirs made little contribution to invasive human disease. 
Any interventions that seek to target food or livestock can affect the numbers of human infections caused by 
ESBL-E coli; prevention of the spread of resistant lineages among humans is more vital.
Funding NIHR Policy Research.
Copyright © 2019 Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Escherichia coli is a Jekyll and Hyde organism; a few 
lineages are virulent enteropathogens whereas most are 
innocuous gut commensals that are harmful only if they 
reach other body sites—notably the urinary tract, where 
E coli is the most common pathogen. Most E coli urinary 
tract infections are uncomplicated cystitis, but some can 
ascend, affecting the kidneys and—at worst—causing 
overspill bacteraemia. Although such sequelae are rare, 
E coli is now the most common bloodstream pathogen in 
England, with 41 060 cases in the 2017–18 fiscal year, 
which was 27% more than in 2012–13 (32 309 cases).1 
Most E coli bacteraemias have a urinary origin2 and, 
in the UK, about 60% are caused by extraintestinal 
pathogenic E coli lineages belonging to sequence types 
(STs) 12, 69, 73, 95, and 131.3
Cephalosporin resistance mediated by extended-spectrum 
β-lactamases (ESBLs) has proliferated in E coli since 2000,4 
and such resistance now occurs in 10–12% of bloodstream 
isolates in the UK.5 This proportion suggests that around 
4900 ESBL-producing E coli (ESBL-E coli) bacteraemias 
occur annually in England and more across the whole UK,1 
often due to multidrug resistant ST131 isolates.3,6 ESBL 
production and multidrug resistance increases the risk 
that empirical treatment will fail, doubling the 17–18% 
mortality that is typical for E coli bacteraemia.7–9
ESBL-E coli are widespread in sewage, pets, meat, and 
food animals, but the extent of transmission between 
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these milieux and humans is uncertain, with the role of the 
food chain under debate.10–12 A meta-analysis10 identified 
six studies suggesting food-to-human trans- mission of 
ESBL-E coli against 17 finding foodborne transmission 
was unimportant. We aimed to clarify the contribution of 
foodborne ESBL-E coli to human colonisation and 
infection, using whole-genome sequencing to compare 
isolates from multiple sources across the UK.
Methods
Study design
We examined ESBL-E coli from multiple sources, 
including human faeces, sewage, farm slurry, live food-
producing animals, and raw meat, fruit, and vegetables. 
By comparing the bacteria from all of these reser voirs 
with ESBL-producing E coli from bloodstream infections 
in five regions of the UK, we sought to provide a 
comprehensive national map and to identify important 
reservoirs of the strains causing human disease in order 
to propose strategic intervention points to reduce the 
burden of ESBL-E coli in the UK.
 Consecutive bloodstream ESBL-E coli isolates were 
collected between Jan 1, 2013, and Oct 12, 2014 from NHS 
laboratories in five UK regions, with five sites in East 
Anglia, two each in northwest England, Scotland, and 
Wales, and one in London. Identification and susceptibility 
testing were done according to laboratories’ local 
protocols, with presumptive ESBL-E coli sent to Public 
Health England Colindale to a quota of 80 per region, 
along with brief, anonymised, patient details.
Isolates from other sources (human faeces, sewage, 
farm slurry, and retail foodstuffs) were collected 
prospectively in the five regions. Isolation involved plating 
samples onto CHROMagar ESBL and CHROMagar CTX 
(CHROMagar, Paris France) chromogenic media, 
prepared according to the manufacturer’s directions. For 
human faecal sampling, which was decentralised, media 
were prepared at PubIic Health England Colindale and 
distributed weekly to laboratories. Characterisation of 
presumptive ESBL-E coli was centralised at PubIic Health 
England Colindale and the Animal and Plant Health 
Agency (APHA) Addlestone.
Human faeces
Faecal specimens were submitted between Aug 12, 2013, 
and July 20, 2014, for detection of intestinal pathogens or 
occult blood screening at Barts Health (London), the 
Norfolk & Norwich University Hospital (East Anglia), 
Lancashire Hospitals Trust, Central Manchester University 
Hospitals (northwest England), Aneurin Bevan University 
Health Board (Wales), and NHS Greater Glasgow and 
Clyde (Scotland). Each laboratory was asked to randomly 
select and test 15–20 faecal specimens per day to a 
maximum of 100 per week. No guidance was given on 
how to select randomly.
Faeces (about 0·5 g) was mixed with 1 mL of 
0·85% saline, then 50-µL aliquots were spread on the 
two chromogenic agars and incubated for 18–24 h. 
Presumptive ESBL-E coli (visible as pink on CHROMagar 
ESBL or blue on CHROMagar CTX) were retained.
Sewage
Paired inflow and effluent sewage samples (50–1000 mL) 
were obtained from multiple sewage works belonging to 
Research in context
Evidence before this study
Extended-spectrum β-lactamase-producing Escherichia coli 
(ESBL-E coli) are the largest group of multidrug-resistant 
pathogens from bacteraemias in the UK, presenting major 
challenges. E coli is also the major aerobic component of the 
human and animal gut biota and is a frequent contaminant of 
meat and the environment. Extensive literature reviews in 
2011–12 were summarised in a joint 2012 report of ESBL-E coli by 
UK Government Advisory Committees. This, and subsequent 
publications, reported considerable uncertainly on the 
contribution of foodborne and environmental ESBL-E coli to 
human colonisation and invasive infection. For example, 
early Dutch studies suggested some similarities between 
ESBL-E coli from humans and poultry farming, whereas a larger 
subsequent study covering the UK, the Netherlands, and Germany 
did not support such a link. A meta-analysis identified six studies 
suggesting food-to-human transmission of ESBL-E coli versus 
17 that argued against this view. These uncertainties led to the 
start of a competitive NIHR Policy Research Programme and, 
among various activities, this programme funded the present 
comparison of ESBL-E coli from human and animal sources.
Added value of this study
This study shows that the ESBL-E coli strains from 
bacteraemias in the UK match those prevalent as human gut 
colonists and in sewage. However, with respect to strain and 
ESBL types, they are largely distinct from those in food 
animals and retail food.
Implications of all the available evidence
In 2016, the UK Government announced its aim to achieve a 
50% reduction in serious Gram-negative infections by 2020. 
A reduction in the numbers of infections due to ESBL-E coli is 
especially desirable, given their incidence (>5000 cases per year) 
and the treatment challenges. Our findings show that actions 
on the food chain, however desirable for animal husbandry, are 
unlikely to contribute to reductions in human infection. Better 
potential control points are prevention of transmission by good 
post-toilet hygiene (eg, in care homes) and prevention of 
severe infection through good patient care and rapid effective 
treatment of initial uncomplicated urinary tract infections, 
which precipitate most of the bacteraemias. Vaccines might 
also be a future solution.
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four water companies covering Scotland, northwest 
England, London, and Wales. East Anglia did not 
participate. Each region provided four batches of samples 
between Dec 9, 2013, and Dec 15, 2014, with about 
80 samples per region. Samples were couriered to PubIic 
Health England Colindale at 2–8°C, stored at 2–10°C, and 
processed within 24 h. Volumes (0·01–10 mL) were 
filtered through 0·45-µm pore membranes, which were 
washed with distilled water before transfer to absorbent 
pads saturated with lauroyl sulphate broth for 4 h at 30°C, 
then to lauroyl sulphate agar for 14 h before enumeration 
of yellow colonies as presumptive E coli. Lastly, one filter 
per sample was transferred to each CHROMagar and 
incubated at 37°C for 18–24 h. Colonies that continued to 
develop, becoming appropriately coloured for ESBL-E coli, 
were retained at 4°C.
 Sewage samples were stored for further analysis by 
pelleting bacteria from about 30 mL sewage, resuspended 
in 0·5 mL of freezing broth and retained at –70°C. 
Putative ESBL-E coli were recovered, as red colonies, after 
plating 100 µL of defrosted material on UTI Brilliance 
Agar (Oxoid, Basingstoke, UK) containing 10 mg/L of 
cefotaxime.
Food
The methods and corresponding results for food isolates 
have been published previously.13 We bought the 
following in each of the five regions: beef, pork, and 
chicken (n=397 samples in a 2:1:2 ratio, reflecting 
market share), grapes (n=50), strawberries (n=38), 
raspberries (n=35), blueberries (n=27), celery (n=50), 
carrots (n=50), onions or spring onions (n=50), lettuce 
(n=50), coriander (n=43), and basil (n=7).13 Retailers 
included leading supermarkets, discount stores, 
convenience stores, and local butchers and greengrocers, 
in proportion to market share. Beef and chicken were 
obtained on five occasions between Aug 1, 2013, and 
Feb 28, 2014; pork on four occasions between Oct 1, 2013, 
and Feb 28, 2014; and vegetables on 15 occasions 
between Jan 1, and March 31, 2014. Meat samples were 
processed by the UK APHA; fruit, vegetables, and herbs 
were done by PubIic Health England, with the 
two chromogenic agars used to recover presumptive 
ESBL-E coli.
Slurry
97 slurry samples were collected from dairy farms across 
the five regions between Jan 13, and March 24, 2014, 
after milking and before cleaning. Samples were taken 
from five different areas at each farm on the route that 
the cows followed when leaving the milking parlour. 
London was represented by the Home Counties 
(Berkshire, Buckinghamshire, Essex, Hertfordshire, 
Kent, Surrey, and Sussex). 1-g samples were incubated 
overnight at 37°C in 9 mL of buffered peptone water 
before plating 10-µL amounts on the two chromogenic 
agars.
Veterinary diagnostic surveillance
We assessed veterinary diagnostic submissions to 
APHA or its predecessor laboratories from prospective 
sur- veillance across the five regions and from scanning 
surveillance of food animals. The latter entails 
laboratory investigations of animal disease, largely post-
mortem or through sample submission. Investigation 
aims to find the cause of disease, and E coli might be 
recovered and characterised. The isolates we studied 
comprised all ESBL-E coli submitted across the 
five regions during 2011–13, irrespective of their 
contribution to disease.
Characterisation of presumptive ESBL-E coli
Presumptive ESBL-E coli, isolated as explained from blood, 
faeces, sewage, food, animals and slurry were received at 
PubIic Health England and screened for blaCTX-M, blaTEM, 
blaSHV and blaOXA by multiplex PCR.14 blaCTX-M-positive isolates 
were accepted as ESBL producers, whereas isolates that 
were positive for one of the other β-lactamase genes 
underwent double disc ESBL tests using amoxicillin–
clavulanate (20 μg + 10 μg) discs about 20 mm apart (centre 
to centre) from cefotaxime (30 μg), ceftazidime (30 μg), and 
cefepime (30 μg) discs. Expansion of an oxyimino-
cephalosporin zone towards the amoxicillin–clavulanate 
disc suggested ESBL production.15 Isolates positive by these 
methods were confirmed as E coli by MALDI-ToF (Bruker 
Maldi-Biotyper, Bremen, Germany); any isolates flagged as 
shigella were confirmed as E coli based on o-nitrophenyl-β-D-
galactosidase activity and a 603-bp PCR product for ipaH.16 
Definitive confirmation as ESBL-E coli was done by whole-
genome sequencing (HiSeq 2500; Illumina, San Diego, CA, 
USA). STs were assigned and β-lactamase genes sought 
using the in-house Genefinder pipeline.17 ST131 isolates 
were assigned to clades based on fimH sequences.18 
Serotypes of ST10 isolates (which crossed among host 
species) were deduced from sequence data.19
Statistical analysis
Our analysis was primarily descriptive, with proportions 
shown as percentages and continuous variables as mean 
and SD. We used Pearson’s χ² test to compare 
proportions. We used R (version 3.5.0) for all analyses.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
ESBL production was confirmed in 293 (90%) of 
327 bloodstream isolates received as ESBL-E coli (table 1). 
Case record forms were available for 244 (83%) of 
293 isolates, with fewer forms available for London 
isolates (18 [33%] of 55; p<0·001). The mean age was 
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70 years (SD 18·7) overall, although participants were 
younger in London (58·9 years; Kruskal-Wallis rank sum 
test p=0·002). 240 (69%) of 347 patients with data were 
community presentations, or stayed in hospital for fewer 
than 48 h. Data on the origin of bacteraemia were 
available for 120 (49%) of 244 patients, with genitourinary 
(72 [60%] of 120) and gastrointestinal or hepatobiliary 
sources (22 [18%] of 120) being the most common. Few 
patients were identified as post-surgical (19 [9%] of 
209 with data), but post-discharge re-presentations might 
be under-recorded.
20 243 faecal samples were screened, comprising 
3995–4112 per region (table 2). 2107 (10%) gave colonies of 
the appropriate colour for E coli on CHROMagar ESBL, 
1302 (6%) on CHROMagar CTX, and 1252 (6%) on both. If 
appropriately coloured growth on either medium—as was 
true for 2157 (11%) of 20 243 faecal specimens—the 
samples were deemed to be positive. Regional ESBL 
prevalence was 8·5–9·8%, except for London, where 
prevalence was 17·0% (p<0·001; table 2). 400 of the 
presumptive ESBL-E coli (80 per region) were forwarded to 
Public Health England, and whole-genome sequencing 
found ESBL genes in 360 (90%) of these. The 40 isolates 
lacking ESBL genes were split between cephalosporin-
susceptible E coli (n=20), E coli with other resistance 
mechanisms (n=18), and non-E coli isolates (n=2). 
Accordingly, ESBL prevalence could be up to 10% lower 
than suggested in table 2; although some detection failures 
might reflect plasmid loss, reducing this correction factor.
Data were available for 355 (99%) of 360 carriers 
(table 2). Their age distribution peaked at less than 
5 years and at 75–79 years. 50–64% of carriers were men, 
according to region, and in-patients accounted for 
30% (London) to 65% (Scotland) of carriers. Overseas 
travel was reported for 99 (28%) of 360 patients, with 
south and southeast Asia being the most common 
destinations (n=33); recent travellers (defined as within 
the past 12 months) accounted for 58% of the patients in 
Wales, 42% in London, and less than 20% elsewhere. 
Clinically significant gastrointestinal pathogens were 
identified by local laboratories in 40 (11%) of 360 patients. 
72 (20%) of 360 patients had recently (defined as within 
East Anglia London Northwest Scotland Wales All
Cases, n 66 55 61 37 74 293
Cases with data, n 55 18 61 37 72 244
Age, mean (SD) 71·5 (24·0) 58·9 (20·4) 65·7 (20·2) 73·3 (17·0) 74·3 (13·9) 70·0 (18·7)
Sex, n (%)
Women 30 (55%) 7 (39%) 34 (56%) 16 (43%) 32 (44%) 119 (49%)
Men 25 (45%) 11 (61%) 27 (44%) 21 (57%) 40 (56%) 125 (51%)
Source of isolate, n (%)
Community or outpatient* 2/25 (8%) 10 (56%) 6/55 (11%) 0 2/48 (4%) 20/184 (11%)
Inpatient
>48 h 5/25 (20%) 4 (22%) 21/55 (38%) 12 (32%) 29/48 (60%) 71/184 (39%)
≤48 h 18/25 (72%) 4 (22%) 28/55 (51%) 25 (68%) 17/48 (35%) 93/184 (50%)
Specialty, n (%)
Accident and emergency 13 (24%) 6 (33%) 12/53 (23%) 20 (54%) 16/46 (22%) 67/209 (32%)
Intensive care 0 3 (17%) 3/53 (6%) 2 (5%) 2/46 (3%) 10/209 (5%)
Medical 29 (53%) 8 (44%) 24/53 (45%) 9 (24%) 25/46 (35%) 95/209 (46%)
Paediatrics 2 (4%) 0 3/53 (6%) 0 0 5/209 (2%)
Surgical 11 (20%) 0 4/53 (8%) 2 (5%) 2/46 (3%) 19/209 (9%)
Other 0 1 (6%) 7/53 (13%) 4 (11%) 1/46 (1%) 13/209 (6%)
Origin, n (%)
Gastrointestinal or biliary 7/40 (18%) 5/15 (33%) 3/27 (11%) 6/31 (19%) 1/7 (14%) 22/120 (18%)
Genitourinary tract 27/40 (68%) 6/15 (40%) 14/27 (52%) 23/31 (74%) 2/7 (29%) 72/120 (60%)
Line related 0 1/15 (7%) 2/27 (7%) 1/31 (3%) 2/7 (29%) 6/120 (5%)
Respiratory 4/40 (10%) 1/15 (7%) 1/27 (4%) 1/31 (3%) 2/7 (29%) 9/120 (8%)
Skin or soft tissue 0 0 2/27 (7%) 0 0 2/120 (2%)
Surgical site infection 0 2/15 (13%) 0 0 0 2/120 (2%)
Other 2/40 (5%) 0 5/27 (19%) 0 0 7/120 (6%)
Denominators are given when the value is not consistent with the number of cases with data. Overall completeness of each variable for East Anglia, London, northwest, Scotland, 
Wales, and all was: age 38%, 33%, 97%, 100%, 97%, and 72%; sex 83%, 33%, 100%, 100%, 97%, and 83%; source of isolate 38%, 33%, 90%, 100%, 65%, and 62%; and origin 61%, 
27%, 44%, 84%, 9%, and 41%. ESBL-E coli=extended-spectrum β-lactamases-producing Escherichia coli. *This category underestimates community onset infection, as evidenced by 
the much larger proportion of patients in the accident and emergency category. Patients presenting at Accident and Emergency with suspected bacteraemia and sepsis are likely to 
be admitted, with their isolates recorded under the inpatient, <48 h category. Figures in the table are shown as percentages of available data.
Table 1: Sources of ESBL-E coli isolates from bloodstream infections
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the past 3 months) taken antimicrobials, of whom 11 had 
received piperacillin or tazobactam.
163 inflow and 162 effluent samples from sewage were 
submitted. Failure of the selective media to adequately 
suppress developing colonies of ESBL-negative E coli 
on the transfer membranes prevented the accurate 
calculation of ESBL prevalence. Nevertheless, a panel of 
65 sewage ESBL-E coli was assembled, 41 from Wales, 
18 from London, and three each from Scotland and 
northwest England.
East Anglia London Northwest Scotland Wales Overall
Faecal samples that gave colonies of the appropriate colour for E coli, n/N (%)
CHROMagar ESBL 309/4107 (7·5%) 678/3995 (17·0%) 366/4019 (9·1%) 393/4010 (9·8%) 361/4112 (8·8%) 2107/20 243 (10·4%)
CHROMagar CTX 169/4107 (4·1%) 363/3995 (9·1%) 258/4019 (6·4%) 282/4010 (7·0%) 230/4112 (5·6%) 1302/20 243 (6·4%)
Either medium 349/4107 (8·5%) 678/3995 (17·0%) 366/4019 (9·1%) 393/4010 (9·8%) 371/4112 (9·0%) 2157/20 243 (10·6%)
Isolates reviewed in detail and sequenced, n 64 77 75 66 73 355
Mean age, years (SD) 56·9 (26·1) 33·4 (25·7) 48·3 (28·5) 60·3 (24·5) 64·2 (22·9) 52·1 (27·8)
Sex
Female 32 (50%) 41 (53%) 38 (51%) 42 (64%) 42 (58%) 195 (55%)
Male 32 (50%) 36 (47%) 36 (48%) 24 (36%) 31 (42%) 159 (45%)
Missing data 0 0 1 (1%) 0 0 1 (<1%)
Overseas travel
Yes 6 (9%) 32 (42%) 13 (17%) 6 (9%) 42 (58%) 99 (28%)
No 58 (91%) 45 (58%) 62 (83%) 60 (91%) 31 (42%) 256 (72%)
Source of isolate
Community 44 (69%) 54 (70%) 42 (56%) 23 (35%) 36 (49%) 199 (56%)
Inpatient (>48 h) 9 (14%) 20 (26%) 20 (27%) 32 (48%) 26 (36%) 107 (30%)
Inpatient (≤48 h) 9 (14%) 3 (4%) 7 (9%) 11 (17%) 11 (15%) 41 (12%)
Missing data 2 (3%) 0 6 (8%) 0 0 8 (2%)
Recent use of antibiotics
Yes 5 (8%) 20 (26%) 12 (16%) 1 (2%) 15 (21%) 72 (20%)
No 13 (20%) 43 (56%) 0 2 (3%) 14 (19%) 53 (15%)
Missing data 46 (72%) 14 (18%) 63 (84%) 63 (95%) 44 (60%) 230 (65%)
Data are n (%) unless otherwise specified. Recent use of antibiotics was defined as use within the past 3 months. ESBL-E coli=extended-spectrum β-lactamases-producing Escherichia coli.
Table 2: Faecal carriage of ESBL-E coli by patient demographics
Bacteraemia Faeces Sewage Meat Slurry Animals
ST Representatives, 
n
ST Representatives, 
n
ST Representatives, 
n
ST Representatives, 
n
ST Representatives, 
n
ST Representatives, 
n
1 131 188 131 128 131 14 602 21 10 6 23 16*
2 38 17 38 29 38 6 23 8 641 3 117 11†
3 648 16 10 15 10 3 117 8 0 0 10 11‡
4 405 9 648 11 0 0 155 6 0 0 6284§ 6¶
5 73 6 69 10 0 0 57 4 0 0 602 4||
6 69 4 405 10 0 0 371 4 0 0 88 4**
7 636 4 410 10 0 0 3776 4 0 0 0 0
8 95 3 636 7 0 0 6285 4 0 0 0 0
9 1193 3 162 6 0 0 665 3 0 0 0 0
10 10 3 443 6 0 0 2040 3 0 0 0 0
Number included 
in above major 
types
·· 253 ·· 232 ·· 35 ·· 65 ·· 9 ·· 52
Total number of 
isolates for all STs
·· 293 ·· 360 ·· 65 ·· 111†† ·· 24 ·· 83‡‡
The top ten STs are listed, except where a group has fewer than three representatives. ST=sequence type. ESBL-E coli=extended-spectrum β-lactamases-producing Escherichia coli. *14/16 from chickens. 
†9/11 from cattle. ‡11/11 from cattle. §Single locus variant of ST117; if these were grouped collectively, they would be the top ST from livestock. ¶6/6 from cattle. ||4/4 from chicken. **2/4 from chicken and 
2/4 from cattle. ††106 chicken, 3 beef, and 2 pork. ‡‡51 cattle, 29 chicken, and 3 other.
Table 3: Major STs among ESBL-E coli found, by sample type and rank
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Results of screening foodstuffs have been published 
separately.13 ESBL-E coli were recovered from 104 (65%) 
of 159 chicken samples, with positivity rates from 
41% (13 of 32 samples in Scotland) to 81% (25 of 
31 samples in northwest England; p<0·0001). 
Contamination could arise from the original bird or be 
acquired during slaughter and processing. Even with 
enrichment, only three (2%) of 159 beef samples and two 
(3%) of 79 pork samples yielded ESBL-E coli, based on 
growth on either of the two chromogenic agars. No 
ESBL-E coli were recovered from 400 fruit and vegetable 
samples, many of which were of international origin.
CTX-M ESBLs SHV TEM: known or possible ESBLs
–15 –27 –14 –1 –24 –2 –3 –9 Other –52 –117 –191 Other
Bacteraemia
131 159 24 5 0 0 0 2 0 0 0 0 0 4 0
38 8 0 8 0 0 0 0 0 0 0 0 0 0 0
648 16 0 0 0 0 0 0 0 0 0 0 0 1 0
405 8 0 1 0 0 0 0 0 0 0 0 0 0 0
73 4 0 0 1 0 0 0 1 0 0 0 0 0 0
All 229 27 20 10 1 2 2 1 0 4 0 1 8 0
Faeces
131 98 18 7 1 0 0 0 0 4* 0 0 1 0 2
38 11 1 15 1 0 0 0 0 0 1 0 0 0 0
10 8 0 1 3 0 0 0 0 1 0 0 1 0 1
648 10 0 1 0 0 0 0 0 0 0 0 0 0 0
69 6 0 2 0 0 0 0 0 1 0 0 0 0 0
All 256 24 38 21 0 0 0 0 20 11 1 6 2 5
Sewage
131 13 1 0 0 0 0 0 0 0 0 0 1 0 3
38 2 0 5 0 0 0 0 0 0 0 0 0 0 5
73 1 0 0 0 0 0 0 0 0 0 0 1 0 0
648 2 0 0 0 0 0 0 0 0 0 0 0 0 1
10 0 0 0 0 0 0 0 0 0 0 0 2 0 1
All 21 1 5 0 0 0 0 0 3 3 0 6 0 14
Meat
602 0 0 0 21 0 0 0 0 0 0 0 0 0 0
23 0 0 0 8 0 0 0 0 0 0 0 1 0 4
117 0 0 0 8 0 0 0 0 0 0 0 0 0 0
155 0 0 0 6 0 0 0 0 0 0 0 0 0 0
57 0 0 0 1 0 0 0 0 0 3 0 0 0 0
All 0 0 0 82 0 2 0 0 4 13 8 3 2 4
Slurry
10 1 0 2 1 0 0 0 0 0 0 0 1 0 0
641 0 0 1 2 0 0 0 0 0 0 0 0 0 1
All 4 1 4 6 0 0 0 0 4† 0 0 2 0 1
Animals
23 1 0 1 12 0 0 0 0 0 0 0 0 0 9
117 1 0 3 2 0 0 3 0 2‡ 0 0 1 1 0
10 3 0 7 0 0 1 0 0 0 0 0 1 0 0
6284 0 0 6 0 0 0 0 0 0 0 0 0 0 0
602 0 0 0 4 0 0 0 0 0 0 0 0 0 0
All 13 0 31 32 0 1 3 1 2 0 0 2 2 9
Chicken 0 0 0 29 0 0 0 0 0 0 0 0 0 9
Cattle 12 0 30 3 0 1 3 1 2 0 0 2 2 0
 Some totals exceed the numbers of isolates belonging to the ST because some isolates had more than one ESBL. The top five STs are included, except those with fewer than 
three representatives. ST=sequence type. ESBL-E coli=extended-spectrum β-lactamases-producing Escherichia coli. *Includes one isolate with Asn173Ser variant of CTX-M-27. 
†Includes one isolate with novel Ser205Arg variant of CTX-M-1. ‡All with CTX-M-214.
Table 4: ESBL types among major STs of E coli from different sources
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19–20 dairy farm slurry samples were tested per region, 
with 27 (28%) of 97 samples positive for ESBL-E coli, 
based on growth on either medium. Regional rates 
ranged from 15% (three of 20 samples in Scotland) to 
40% (eight of 20 samples in northwest England).
These prospective collections were supplemented 
with 83 ESBL-E coli from the APHA’s scanning 
surveillance of food animals. These were from the same 
regions as the other series, with London again including 
the Home Counties; 51 isolates were from cattle, 
29 from chickens with single isolates from other 
species.
ST131 greatly predominated in human bacteraemias, 
comprising 188 (64%) of 293 isolates. It was also the 
most prevalent ST, though less overwhelmingly so, in 
faeces (128 [36%] of 360 isolates) and sewage (14 [22%] of 
65). Regional proportions of ST131 among bloodstream 
isolates were 36 (65%) of 55 in London, 40 (60%) of 66 in 
East Anglia, 29 (48%) of 61 in northwest England, 
28 (76%) of 37 in Scotland, and 55 (74%) of 74 in Wales 
Figure: Escherichia coli strains and ESBL types dominating in specimen types that relate to humans and animals
The inner circle presents the sources of ESBL-E coli; segments are scaled according to the numbers of isolates found and single representatives of an ST are aggregated 
into the singleton category. The middle circle represents the numbers of isolates from each ST in relation to each ESBL. The outer circle represents the number of 
isolates with an ESBL type. ST=sequence type. ESBL-E coli=extended-spectrum β-lactamases-producing E coli.
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(p=0·011). Corresponding proportions among faecal 
isolates were 16 (21%) of 77 in London, 16 (24%) of 67 in 
East Anglia, 27 (36%) of 75 in northwest England, 
37 (54%) of 68 in Scotland, and 32 (44%) of 72 in Wales 
(p<0·0001).
Other common bloodstream STs, in descending order 
of frequency, were 38, 648, 405, 73, 69, 636, 95, 1193, and 
10. Several of these were also prominent in other human-
related sources. STs 38, 405, 636, and 648 were among the 
top ten types among faecal isolates, with ST38 in second 
rank and ST648 in fourth; ST38 was the second ranked ST 
from sewage, followed by ST10. By contrast, the top-
ranked STs from meat and animals were 602, 23, 117 (or 
its single locus variant ST6284), and ST10. Collectively, 
STs 23, 117, and 602 accounted for 68 (31%) of 218 food-
derived and animal-derived ESBL-E coli samples collected, 
whereas ST10 accounted for 11 (22%) of 51 bovine 
ESBL-E coli samples. There was species specificity within 
the animal isolates, with STs 23 and 602 dominating for 
chickens and chicken meat, whereas STs 10, 117 and 
6284 dominated in cattle and their slurry (table 3).
The top-ranked human types were rare in meat, 
animals, and slurry. Just two ST131 isolates were 
recovered from animal-related sources: one from chicken 
meat and another from a surveillance chicken; both 
isolates belonged to ST131 clade B whereas over 95% of 
bloodstream, faecal, and sewage ST131 isolates belonged 
to clades C1 and (mostly) C2. STs 38, 648, 405, 73, 636, 95, 
and 1193 were not found in animal-associated sources, 
and ST69 was found in just one isolate from chicken 
meat and one from a cow. Only ST10, which accounted 
for 15 (4%) of 360 human faecal isolates and three (1%) of 
293 isolates from blood was widely seen in bovines and 
their slurry, though not in meat (table 3). This human 
and animal overlap for ST10 was more apparent than real; 
we found that 38 ST10 isolates belonged to 26 different 
combinations of O (somatic) and H (flagellar) serotype, 
with the three human bloodstream isolates and 12 (87%) 
of 15 human faecal isolates belonging to serotypes that 
were not seen from animal sources.
The predominant animal-related STs were infrequent 
in humans. ST602, the top ST from meat (specifically 
chicken), was not found in human bacteraemias and had 
only two representatives from human faeces. Among all 
293 human bacteraemia isolates, only five (2%) belonged 
to top-ranked types from any animal-related source, 
specifically the three ST10 isolates and single 
representatives of STs 23 and 117.
CTX-M-15 enzyme was most common in human 
bloodstream, faecal, and sewage isolates (table 4). This 
finding reflected CTX-M-15’s association with ST131, but it 
remained the most prevalent ESBL in other major STs from 
these sources except ST38, where CTX-M-14 narrowly 
dominated. 24 (14%) of 188 ST131 isolates had CTX-M-27, 
not CTX-M-15. Overall, CTX-M-15 accounted for 319 (77%) 
of 416 ESBLs found in the predominant human-linked 
lineages: ST131, ST38, and ST648.
CTX-M-1 was the most common ESBL found in meat 
(chicken) isolates, whereas CTX-M-15 was not found and 
most other ESBLs were SHV or TEM types. CTX-M-1 also 
dominated (20 of 29 cases) in surveillance chickens, whilst 
CTX-M-14 dominated in cattle, with 30 examples versus 
12 for CTX-M-15, three for CTX-M-27, and seven for other 
CTX-M types. STs 23 and 602 were the major hosts of 
CTX-M-1 enzyme in chickens and their meat, whereas 
ST10 and ST117/ST6284 were the frequent hosts of 
CTX-M-14 among bovines. Despite its frequency in E coli 
from chickens and their meat, CTX-M-1 enzyme was 
found in only ten (3%) of 293 human bloodstream isolates, 
21 (6%) of 360 from faeces, and seven (11%) of 65 from 
sewage. CTX-M-1 enzyme mostly occurred in minor 
human STs, with only one or two representatives each. 
The only exception was ST10, for which CTX-M-1 was 
found in three (60%) of 15 human faecal isolates. The 
ST23/CTX-M-1 and ST602/CTX-M-1 combinations, which 
were widespread in chickens and their meat, were found 
only in single human faecal isolates and were never found 
in blood. CTX-M-14, the most frequent ESBL from the 
bovine isolates, was widely found in major human blood 
and faecal isolates, including ST131 and ST38, but the 
ST10/CTX-M-14 combination, frequent in cattle, had only 
single representatives from human faeces and blood, 
whereas ST117/ST6284 CTX-M-14 was not detected. 
There was a single bloodstream ST117 isolate with 
CTX-M-1 enzyme, matching a combination seen in ten 
isolates from chickens or their meat.
Discussion
We compared ESBL-E coli from human bacteraemias 
with those from human faeces, sewage, food, slurry, and 
animals across five regions in the UK. Bloodstream 
isolates followed expected patterns; they were mostly 
found in older patients with community-associated 
infection of genitourinary or gastrointestinal origin.2 
Faecal ESBL-E coli were often linked to foreign travel 
(particularly to south or southeast Asia) or previous use 
of antibiotics, which is consistent with the literature.20,21 
Greater contamination of chicken than other meats 
concurs with previous findings.22
Typing and ESBL results showed commonality between 
human bloodstream ESBL-E coli and those from 
faeces and sewage, with STs 131 (especially), 38, and 
648 prominent in all these sources, largely with 
CTX-M-15 enzyme. There was also commonality between 
the lineages from surveillance chickens and chicken meat, 
with STs 23 and 602 dominating, often with CTX-M-1 ESBL, 
and between cattle and their slurry, where ST10 (with 
CTX-M-14 or CTX-M-15) dominated. There was little 
crossover between types from humans, chickens, and 
bovines, with only serotype diverse ST10 among the top 
ten most common types from humans, animals, and meat 
(figure). ST117 was widely found in isolates from both 
bovines and chickens. Little contamination was seen for 
foodstuffs other than chicken.
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Our findings do not support the assertion that invasive 
ESBL-E coli are disseminating via the food chain. Rather, 
they suggest that host-adapted ESBL-E coli lineages are 
circulating, with infrequent interspecies transmission. 
This conclusion agrees with most studies included in a 
2015 meta-analysis.10 ST131, which dominated among 
human-related isolates, is well known and often 
multidrug resistant.6,23 Although ST131 occasionally 
occurs in food animals (as was seen in two instances in 
our analysis), the animal ST131 clades are generally 
different.24 At the upper edge of the reported prevalence 
range, Johnson and colleagues25 in the USA found five of 
25 ESBL-E coli from chickens or chicken meat belonged 
to ST131. By contrast, we—and a previous investigation 
covering the UK, Germany, and the Netherlands22—
found only occasional ST131 isolates from food and 
animals. This rarity is supported by a major review,6 
cataloguing many individual detections of ST131 from 
food or food animals, but no dissemination.
Other common types from bacteraemia—ST38 and 
ST648, each accounting for about 5% of cases versus 
64% for ST131—were absent from food or animals. ST38 
(with CMY-2, rather than ESBLs) has been found in 
poultry, humans, and wildlife;26 ST648 is also largely 
reported from humans, although carriage was seen in 
horses and dogs.27 Among the major meat and animal 
types, ST23 was reported from an outbreak in a French 
hospital,28 with various further one-off reports but, as we 
report here, is mostly found in poultry,29 as is ST117,23 
which has spread in Nordic broiler production.30 ST602, 
although common in our study, has not been widely 
reported in previous studies.22 ST10, as the sole lineage to 
appear in the top ten of both human bloodstream and 
meat-associated groups has been repeatedly noted by 
other studies22 in both animals and humans. Nonetheless, 
the serotype diversity seen in our analysis argues against 
simple direct flows of ST10 along the food chain. Our 
results are consistent with those of a comparison of 
ESBL-E coli from human bacteraemias and livestock in 
the east of England, one of the regions we surveyed, 
which also found that these isolate groups and their 
resistance determinants are largely distinct.31
Rather than the food chain, the human to human oral-
faecal route is likely to be the most frequent route of 
transmission for human-adapted ESBL-E coli. This route 
would account not only for the strain and enzyme 
distributions we have summarised, but also the regional 
variation in gut carriage of ESBL-E coli with higher rates 
in London than elsewhere, where sampling was solely 
from the Royal London Hospital, which predominantly 
serves poor, crowded areas and populations with frequent 
travel to and from south Asia. A study in the West 
Midlands, UK, similarly showed that human gut carriage 
of ESBL-E coli was more prevalent in inner city 
conurbations (ie, around Birmingham) than in rural 
Shropshire.32 We cannot exclude the possibility that some 
small minority of human infections might have a direct 
origin from food, nor that local clusters can occur. 
In Canada,33,34 near-identical ST131 and ST117 E coli 
(ESBL-producing or not) have been found in both retail 
chicken meat and human infections; nevertheless these 
putative crossovers accounted for only a small minority 
of all the human and animal E coli collected. Further, we 
cannot exclude the possibility that some future multidrug 
resistant E coli lineage from one or more food animal 
species will also prove adept at colonising and infecting 
humans. One further caveat remains: we do not know 
when, where, or how often blaCTX-M genes escaped 
from Kluyvera spp (where they are endogenous and 
chromosomal) to mobile DNA, nor the chain of 
transmission to human-adapted E coli lineages. However, 
it seems logical that the hazard of such gene escape will 
multiply with the range of animal species and intestinal 
microbiotas exposed to selective antibiotics.35
Our findings suggest that efforts to stop the rise of 
ESBL-E coli in invasive infections should concentrate 
upon disrupting oral-faecal transmission by good post-
toilet hygiene (eg, in care homes), on prevention of 
urinary tract infections by good hydration and catheter 
care, and on prompt effective treatment of preceding 
urinary tract infections. Vaccines could provide a solution 
in the future, with promising early results for cystitis 
in younger women.36 Efforts to counter the spread of 
ESBL-E coli in food production seem unlikely to affect 
greatly the tally of invasive human infections but remain 
important in ensuring that veterinary infections remain 
tractable.
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